• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . SARS-CoV-2 viral load is associated with increased disease severity and mortality

tetano

Editor, Senior Moderator
Nat Commun


. 2020 Oct 30;11(1):5493.
doi: 10.1038/s41467-020-19057-5.
SARS-CoV-2 viral load is associated with increased disease severity and mortality


Jesse Fajnzylber[SUP] 1 [/SUP], James Regan[SUP] 1 [/SUP], Kendyll Coxen[SUP] 1 [/SUP], Heather Corry[SUP] 1 [/SUP], Colline Wong[SUP] 1 [/SUP], Alexandra Rosenthal[SUP] 1 [/SUP], Daniel Worrall[SUP] 2 [/SUP], Francoise Giguel[SUP] 3 [/SUP], Alicja Piechocka-Trocha[SUP] 2 [/SUP], Caroline Atyeo[SUP] 2 [/SUP], Stephanie Fischinger[SUP] 2 [/SUP], Andrew Chan[SUP] 3 [/SUP], Keith T Flaherty[SUP] 3 [/SUP], Kathryn Hall[SUP] 3 [/SUP], Michael Dougan[SUP] 3 [/SUP], Edward T Ryan[SUP] 3 [/SUP], Elizabeth Gillespie[SUP] 1 [/SUP], Rida Chishti[SUP] 1 [/SUP], Yijia Li[SUP] 1 [/SUP], Nikolaus Jilg[SUP] 1 3 [/SUP], Dusan Hanidziar[SUP] 3 [/SUP], Rebecca M Baron[SUP] 1 [/SUP], Lindsey Baden[SUP] 1 [/SUP], Athe M Tsibris[SUP] 1 [/SUP], Katrina A Armstrong[SUP] 3 [/SUP], Daniel R Kuritzkes[SUP] 1 [/SUP], Galit Alter[SUP] 2 3 [/SUP], Bruce D Walker[SUP] 2 3 4 [/SUP], Xu Yu[SUP] 2 3 [/SUP], Jonathan Z Li[SUP] 5 [/SUP], Massachusetts Consortium for Pathogen Readiness



Collaborators, Affiliations

Abstract

The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.
 
Back
Top Bottom